To verify whether the synergism between CR and LSD1 inhibition can be exploited in other, more common neoplasms, first we explored the impact of CR and LSD1-inhibition in a PDX of an AML bearing an MLL-AF9 translocation, transplanted in NSG mice and CR-unresponsive. The gene discussed is MLLT3; the disease is acute myeloid leukemia.